Crusted and eroded plaques in metastatic lung cancer

Crusted and eroded plaques in metastatic lung cancer

Saved in:

Bibliographic Details
Main Authors:	Robin Wang, MD, Zisansha Zahirsha, MD, Brandon Zelman, DO, Jodi Speiser, MD, Madhu Dahiya, MD, David Eilers, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	JAAD Case Reports
Subjects:	atezolizumab bullous pemphigoid immune checkpoint inhibitors immune-related cutaneous adverse events metastatic lung cancer programmed death-ligand 1 inhibitor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512624004168
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pathogenesis, diagnosis and treatment of immune checkpoint inhibitor related bullous pemphigoid
by: Yi SUN, et al.
Published: (2025-04-01)

Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
by: Nika Kotnik, MD, et al.
Published: (2025-07-01)

Bullous pemphigoid treated with baricitinib as steroid-sparing therapy for a patient with uncontrolled diabetes
by: Ji Won Heo, MD, et al.
Published: (2025-03-01)

Successful Treatment of Immune Checkpoint Inhibitor–Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature
by: Chen J, et al.
Published: (2024-12-01)

Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib
by: Tamás Malkovics, et al.
Published: (2024-12-01)

Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing
by: Taisei Mushiroda
Published: (2025-07-01)

Recent advances in the genetics and innate immune cells of bullous pemphigoid
by: Xiaoli Yang, et al.
Published: (2025-06-01)

JAK-STAT pathway, type I/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid
by: Xiaoying Lin, et al.
Published: (2025-04-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
by: Natalie Bourand, MS, et al.
Published: (2025-02-01)

Severe case of bullous pemphigoid associated with nivolumab responsive to combination therapy with dupilumab and omalizumab
by: Liana Victory, MB, BCh, BAO, MRCPI, et al.
Published: (2025-03-01)

Dyshidrosiform Bullous Pemphigoid With Dermatophyte Infection: An Association or Coincidence? Diagnostic Challenge of a Case and Review of the Literature
by: Joshana Shrestha, et al.
Published: (2025-02-01)

Bullous pemphigoid after Split Skin grafting in vitiligo patient
by: Siddharth Bhatt, et al.
Published: (2024-12-01)

Seborrheic pemphigoid
by: Marcelina Kądziela, et al.
Published: (2025-02-01)

Prior corticosteroid treatment alters cPBMC composition and IFNγ response to immunotherapy in canine cancer
by: Anna Barbara Emilia Zimmermann, et al.
Published: (2025-04-01)

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01)

Research progress on the association of bullous pemphigoid with type 2 diabetes mellitus
by: ZHANG Ruohan, et al.
Published: (2025-03-01)

Bullous Pemphigoid and Epidemiological Patterns in Northern Greece: Insights from an 8-Year Observational Study
by: Athina-Ioanna Daponte, et al.
Published: (2025-04-01)

Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
by: Iva Skocilic, et al.
Published: (2025-04-01)

Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study
by: Merin Babu, et al.
Published: (2025-07-01)

Immune checkpoint inhibitor-induced dyshidrotic eczema following tremelimumab therapy for hepatocellular carcinoma
by: Raphaella Lambert, BA, et al.
Published: (2025-04-01)

Bullous pemphigoid and morphea: Coexistence or an incidental association
by: Seema Rani, et al.
Published: (2024-12-01)

Anti‐Angiogenic Agents for Advanced Hepatocellular Carcinoma Induce Liver Atrophy
by: Taijiro Wake, et al.
Published: (2025-08-01)

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC
by: Risako Kohya, et al.
Published: (2025-05-01)

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
by: Binghua Li, et al.
Published: (2025-01-01)

Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
by: Hyuk Kim, et al.
Published: (2024-08-01)

Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230
by: Feliciana Mariotti, et al.
Published: (2024-11-01)

Bullous pemphigoid as a diagnostic and therapeutic challenge with a wide spectrum of dermatological symptoms
by: Przemysław Borowy, et al.
Published: (2025-01-01)

Localized genital blisters in an elderly male
by: An Jian Leung, MBBS, MRCP, MMed, et al.
Published: (2025-05-01)

Analysis of rare events in healthcare intervention using department of defense data: intravenous immune globulin therapy for bullous pemphigoid
by: Onur Baser, et al.
Published: (2025-04-01)

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis
by: Qingzi Yan, et al.
Published: (2025-01-01)

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression
by: K. Morimoto, et al.
Published: (2025-06-01)

Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis
by: Jun Xie, et al.
Published: (2025-04-01)

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery
by: Elisabetta Goio, et al.
Published: (2020-09-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
by: Emma L. Myers, BA, et al.
Published: (2025-04-01)

Bullous pemphigoid and its association with neurological diseases
by: Charl P. Smit, et al.
Published: (2024-02-01)

Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis
by: Júlia Opolski Nunes da Silva, et al.
Published: (2025-08-01)

Necrotizing fasciitis – a complication of autoimmune skin blistering diseases?
by: Milana Jurišić, et al.
Published: (2023-05-01)

Causal Relationship Between Psoriasis and Bullous Pemphigoid: A Mendelian Randomization Analysis
by: Xiaoxue Wang, et al.
Published: (2025-01-01)

Paraneoplastic bullous pemphigoid secondary to cutaneous squamous cell carcinoma
by: Karolina Zarańska, et al.
Published: (2025-01-01)